Compare VRTX & LMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | LMT |
|---|---|---|
| Founded | 1989 | 1912 |
| Country | United States | United States |
| Employees | 6100 | N/A |
| Industry | EDP Services | Military/Government/Technical |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 109.9B |
| IPO Year | 1991 | N/A |
| Metric | VRTX | LMT |
|---|---|---|
| Price | $457.11 | $484.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 25 | 15 |
| Target Price | $494.64 | ★ $515.40 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 02-09-2026 | 01-27-2026 |
| Dividend Yield | N/A | ★ 2.91% |
| EPS Growth | ★ N/A | N/A |
| EPS | 14.22 | ★ 17.88 |
| Revenue | $11,723,300,000.00 | ★ $73,349,000,000.00 |
| Revenue This Year | $11.01 | $6.01 |
| Revenue Next Year | $8.74 | $4.23 |
| P/E Ratio | $32.08 | ★ $26.51 |
| Revenue Growth | ★ 10.33 | 2.88 |
| 52 Week Low | $362.50 | $410.11 |
| 52 Week High | $519.68 | $516.00 |
| Indicator | VRTX | LMT |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 60.75 |
| Support Level | $445.41 | $464.88 |
| Resistance Level | $459.05 | $484.77 |
| Average True Range (ATR) | 10.50 | 9.62 |
| MACD | 0.26 | 2.69 |
| Stochastic Oscillator | 83.14 | 96.85 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.